Physician profile
Beverly Lippert
NPI 1205383130
$3,404.31
in general payments reported to CMS, 2019-2025
24 companies · $711 in 2025
The $711 reported for 2025 was more than what 82% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $389 · 2022: $690 · 2023: $599 · 2024: $1,014 · 2025: $711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,324.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $699.98 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $669.24 | 2021-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $247.40 | 2021-2025 | Farxiga, Brilinta |
| Cvrx, INC. | $239.51 | 2023-2025 | Barostim Neo System |
| Cardiva Medical, INC. | $224.99 | 2022-2024 | Optowire, Cardiva Vascade Mvp Vvcs 6-12f, Ensoetm |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.10 | 2023-2025 | Jardiance |
| Boston Scientific Corporation | $180.92 | 2022-2025 | Watchman Flx, General - Crm_crm |
| Bayer Healthcare Pharmaceuticals INC. | $155.87 | 2021-2025 | |
| Abiomed | $148.65 | 2024-2025 | Impella |
| E.R. Squibb & Sons, L.L.C. | $114.19 | 2023-2025 | Camzyos, Eliquis |
| Lexicon Pharmaceuticals, INC. | $102.41 | 2023-2024 | Inpefa |
| Medtronic, INC. | $67.16 | 2025 | Ffrangio |
| Kiniksa Pharmaceuticals, LTD. | $47.45 | 2022-2023 | Arcalyst |
| Abbott Laboratories | $41.20 | 2022-2025 | Merlin@Home |
| Kiniksa Pharmaceuticals International, Plc | $39.05 | 2024 | Arcalyst |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $36.33 | 2021-2025 | |
| Atricure, INC. | $31.14 | 2024 | |
| Merck Sharp & Dohme LLC | $30.30 | 2023 | Verquvo |
| Vifor Pharma, INC. | $22.29 | 2021 | |
| Inspire Medical Systems, INC. | $21.33 | 2025 | Inspire |
| Philips North America LLC | $20.76 | 2022 | |
| Sanofi-Aventis U.S. LLC | $19.99 | 2021 | |
| Chiesi USA, INC. | $16.11 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beverly Lippert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.